hVIVO plc (LON:HVO – Get Free Report) was up 10.3% during trading on Monday . The company traded as high as GBX 21.50 ($0.27) and last traded at GBX 21.31 ($0.27). Approximately 3,194,943 shares were traded during trading, an increase of 18% from the average daily volume of 2,705,167 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Price Performance
The stock has a 50 day moving average of GBX 20.14 and a two-hundred day moving average of GBX 25.64. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm has a market capitalization of £128.25 million, a P/E ratio of 628.33 and a beta of 0.97.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Stories
- Five stocks we like better than hVIVO
- How to Start Investing in Real Estate
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- What Does the Future Hold for Eli Lilly?
- What is a Dividend King?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
